{"id":34431,"date":"2025-05-29T17:01:12","date_gmt":"2025-05-29T09:01:12","guid":{"rendered":"https:\/\/flcube.com\/?p=34431"},"modified":"2025-05-29T17:01:13","modified_gmt":"2025-05-29T09:01:13","slug":"novartis-fabhalta-approved-for-previously-treated-pnh-patients-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34431","title":{"rendered":"Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China"},"content":{"rendered":"\n

The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS<\/a>) announced that the National Medical Products Administration (NMPA) has approved an additional indication for its oral monotherapy Fabhalta (iptacopan). The expanded approval now includes the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were previously treated with complement inhibitors, providing a new therapeutic option for this patient population.<\/p>\n\n\n\n

Fabhalta’s Regulatory Milestone in China<\/strong>
Fabhalta, the world’s first oral, targeted factor B inhibitor of the complement system, now boasts three approved indications in China. These include adult PNH patients who were previously untreated with complement inhibitors and adult patients with C3 glomerulopathy (C3G). This latest approval underscores the drug’s growing role in the treatment landscape for complement-mediated diseases.<\/p>\n\n\n\n

Ongoing Development and Future Prospects<\/strong>
Novartis continues to develop Fabhalta for a range of complement-mediated conditions beyond PNH and C3G. The drug is currently under investigation for potential applications in atypical hemolytic uremic syndrome (aHUS), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and lupus nephritis (LN), further highlighting its broad therapeutic potential.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical…<\/p>\n","protected":false},"author":1,"featured_media":34432,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[865,15,24],"class_list":["post-34431","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nyse-nvs","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"\nNovartis' Fabhalta Approved for Previously Treated PNH Patients in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved an additional indication for its oral monotherapy Fabhalta (iptacopan). The expanded approval now includes the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were previously treated with complement inhibitors, providing a new therapeutic option for this patient population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34431\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis' Fabhalta Approved for Previously Treated PNH Patients in China\" \/>\n<meta property=\"og:description\" content=\"The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved an additional indication for its oral monotherapy Fabhalta (iptacopan). The expanded approval now includes the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were previously treated with complement inhibitors, providing a new therapeutic option for this patient population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34431\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-29T09:01:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-29T09:01:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2909.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34431#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34431\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China\",\"datePublished\":\"2025-05-29T09:01:12+00:00\",\"dateModified\":\"2025-05-29T09:01:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34431\"},\"wordCount\":188,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34431#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2909.webp\",\"keywords\":[\"NYSE: NVS\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34431#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34431\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34431\",\"name\":\"Novartis' Fabhalta Approved for Previously Treated PNH Patients in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34431#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34431#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2909.webp\",\"datePublished\":\"2025-05-29T09:01:12+00:00\",\"dateModified\":\"2025-05-29T09:01:13+00:00\",\"description\":\"The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved an additional indication for its oral monotherapy Fabhalta (iptacopan). The expanded approval now includes the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were previously treated with complement inhibitors, providing a new therapeutic option for this patient population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34431#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34431\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34431#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2909.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2909.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis' Fabhalta Approved for Previously Treated PNH Patients in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34431#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis' Fabhalta Approved for Previously Treated PNH Patients in China - Insight, China's Pharmaceutical Industry","description":"The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved an additional indication for its oral monotherapy Fabhalta (iptacopan). The expanded approval now includes the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were previously treated with complement inhibitors, providing a new therapeutic option for this patient population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34431","og_locale":"en_US","og_type":"article","og_title":"Novartis' Fabhalta Approved for Previously Treated PNH Patients in China","og_description":"The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved an additional indication for its oral monotherapy Fabhalta (iptacopan). The expanded approval now includes the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were previously treated with complement inhibitors, providing a new therapeutic option for this patient population.","og_url":"https:\/\/flcube.com\/?p=34431","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-29T09:01:12+00:00","article_modified_time":"2025-05-29T09:01:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2909.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34431#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34431"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China","datePublished":"2025-05-29T09:01:12+00:00","dateModified":"2025-05-29T09:01:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34431"},"wordCount":188,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34431#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2909.webp","keywords":["NYSE: NVS","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34431#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34431","url":"https:\/\/flcube.com\/?p=34431","name":"Novartis' Fabhalta Approved for Previously Treated PNH Patients in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34431#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34431#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2909.webp","datePublished":"2025-05-29T09:01:12+00:00","dateModified":"2025-05-29T09:01:13+00:00","description":"The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved an additional indication for its oral monotherapy Fabhalta (iptacopan). The expanded approval now includes the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were previously treated with complement inhibitors, providing a new therapeutic option for this patient population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34431#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34431"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34431#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2909.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2909.webp","width":1080,"height":608,"caption":"Novartis' Fabhalta Approved for Previously Treated PNH Patients in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34431#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2909.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34431"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34431\/revisions"}],"predecessor-version":[{"id":34433,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34431\/revisions\/34433"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34432"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}